135P Camrelizumab plus chemotherapy as first-line therapy for NSCLC: A pooled analysis of two randomized phase III trials with extended follow-up

Changdong Zhou ,Y Zhang,Y Tai,J Chen,J Zhou,Z Wang,W Zhang,G Chen,Q Wang,Yubei Huang ,Y Fang,X Lu,J Feng,L Lin,Y Pan,J Shi,Y Liu,X Xu,Y Cheng,X Ma

doi:10.1016/j.iotech.2022.100247

135P Camrelizumab plus chemotherapy as first-line therapy for NSCLC: A pooled analysis of two randomized phase III trials with extended follow-up

Changdong Zhou , Y Zhang + Show 18 more

Open Access

https://doi.org/10.1016/j.iotech.2022.100247

Copy DOI

Journal: Immuno-Oncology and Technology	Publication Date: Dec 1, 2022
Citations: 1	License type: cc-by-nc-nd

#Squamous NSCLC #Advanced Squamous NSCLC + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The phase 3 CameL and CameL-sq studies have proven the superiority of first-line camrelizumab plus chemotherapy (camre-chemo) vs chemo for progression-free survival (PFS) in patients (pts) with advanced non-squamous and squamous NSCLC, respectively. Here, we report pooled outcomes of pts from the two trials with long-term follow-up.

Full Text